Oncology · Radioactive Drug TherapyTrial Updateclinicalmid-term

177Lu-DOTA-EB-TATE Trial for Metastatic Hurthle-Cell Thyroid Cancer Initiated

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/8/2026, 12:30:40 AM

Assessment confidence: 59% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of the 177Lu-DOTA-EB-TATE trial represents a significant advancement in addressing a rare cancer with limited treatment options. Success in this trial could not only enhance the therapeutic landscape for metastatic Hurthle-cell thyroid cancer but also shift competitive dynamics within the oncology sector. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 23 ranked evidence items (8 high-relevance).

Strategic Assessment

If successful, this could enhance the portfolio of radioactive therapies and provide a new treatment paradigm for HTC, impacting competitive dynamics in oncology. The strongest clinical anchor is 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer (ClinicalTrials.gov), entity match (hurthle-cell thyroid cancer); patient population match (metastatic). In Oncology · Radioactive Drug Therapy, 4 regulatory and 4 competitive items passed relevance filtering for Hurthle-cell thyroid cancer.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC. This trial addresses a significant unmet need in a rare cancer with limited treatment options, potentially positioning the drug as a novel therapeutic approach.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). Relevant agencies in corpus: FDA, MHRA. The outcome of this trial may pave the way for regulatory approvals of new treatment options for Hurthle-cell thyroid cancer, impacting compliance and labeling for future therapies in this space.

Key Risks

Elevated medium regulatory exposure for Hurthle-cell thyroid cancer could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If the trial demonstrates efficacy, it could lead to market entry of a novel therapy, potentially capturing market share in a niche segment of oncology and influencing revenue streams for companies involved in similar therapeutic areas.
Upside for Hurthle-cell thyroid cancer may improve if HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer (ClinicalTrials.gov) delivers favorable follow-through.
Lead sponsor: Janssen Research & Development, LLC.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.

What Would Change This Assessment

This becomes more urgent if Monitor trial progress, patient enrollment rates, and initial efficacy results over the next 1-2 years.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
ClinicalTrials.govhigh relevance
Entity match (hurthle-cell thyroid cancer); Patient population match (metastatic)
FDA document
View source
HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Roche); Patient population match (metastatic)
FDA document
View source
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
ClinicalTrials.govhigh relevance
Patient population match (metastatic)
FDA document
View source
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalsmedium relevance
Sponsor/company relevance (Pfizer)
NCI Trials CD19/CD22 CAR T Cells for Refractory B Cell Malignancies in Young Patients
Humanexa Signalsmedium relevance
Moderate corpus alignment
Phase III Trial of Toripalimab and Lenvatinib for Advanced HCC Initiated
Humanexa Signalsmedium relevance
Moderate corpus alignment

Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
PubMedhigh relevance
Patient population match (metastatic)
FDA document
View source
Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.
PubMedhigh relevance
Patient population match (metastatic)
FDA document
View source
Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study.
PubMedhigh relevance
Patient population match (metastatic)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Deep learning based on CD3 histological slides for prediction of colon cancer outcome: analysis of three international stage III colon cancer cohorts.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lysosome-directed targeted protein degradation technologies for overcoming cancer drug resistance: mechanisms, design principles, and therapeutic opportunities.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Hurthle-cell thyroid cancer
National Institute of Diabetes and Digestive and Kidney Diseases

Commercial impact

medium

If the trial demonstrates efficacy, it could lead to market entry of a novel therapy, potentially capturing market share in a niche segment of oncology and influencing revenue streams for companies involved in similar therapeutic areas.

Regulatory impact

medium

The outcome of this trial may pave the way for regulatory approvals of new treatment options for Hurthle-cell thyroid cancer, impacting compliance and labeling for future therapies in this space.

What to watch

Monitor trial progress, patient enrollment rates, and initial efficacy results over the next 1-2 years.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.